You are here:
aliskiren (Rasilez)
Advice
Following a resubmission
aliskiren (Rasilez) is not recommended for use within NHS Scotland for the treatment of essential hypertension.
Aliskiren has shown comparable efficacy to other antihypertensive agents in terms of blood pressure reduction, though its effects on mortality and long-term morbidity are currently unknown.
The manufacturer did not present a sufficiently robust clinical or economic analysis to gain acceptance by the SMC for the position sought.
Drug Details
| Drug Name: | aliskiren (Rasilez) |
|---|---|
| SMC Drug ID: | 462/08 |
| Manufacturer: | Novartis Pharmaceuticals UK Ltd |
| Indication: | Essential Hypertension |
| BNF Category: | |
| Sub Category: | 2.6 Nitrates*** calcium-channel blockers*** and other antianginal drugs |
| Submission Type: | Resubmission |
| Status: | Not Recommended |
| Date Advice Published: | 8 February 2010 |
Archived Advice
| aliskiren (Rasilez)_fullsub | Full submission | 12 January 2009 |
| aliskiren (Rasilez)_nonsub | Non submission | 12 May 2008 |